Loading...
XNAS
GALT
Market cap239mUSD
Oct 08, Last price  
3.64USD
1D
0.55%
1Q
-10.34%
Jan 2017
271.50%
IPO
-69.67%
Name

Galectin Therapeutics Inc

Chart & performance

D1W1MN
XNAS:GALT chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
2.30%
Rev. gr., 5y
%
Revenues
0
Net income
-31m
L-34.46%
-3,193,000-9,433,000-3,151,000-7,462,000-5,629,000-10,915,000-9,675,000-12,088,000-15,788,000-20,027,000-21,436,000-16,235,000-13,900,000-13,294,000-23,465,000-30,527,000-38,776,000-41,066,000-47,047,000-30,836,000
CFO
-24m
L-42.84%
-6,757,000-5,483,000-4,665,000-3,887,000-3,102,000-5,676,000-7,500,000-7,484,000-12,426,000-16,983,000-16,409,000-15,892,000-10,179,000-10,848,000-20,601,000-24,308,000-31,056,000-32,965,000-41,767,000-23,875,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Key people

Jack Callicutt
Chief Financial Officer · since 2013
Khurram Jamil
Chief Medical Officer · since 2024
Benjamin Carson
Director · since 2023
Joel Lewis
President, Chief Executive Officer, Director · since 2020
Paul Pressler
Director · since 2011
Gilbert Amelio
Independent Director · since 2009
Kary Eldred
Independent Director · since 2018
Kevin Freeman
Independent Director · since 2011
Gilbert Omenn
Independent Director · since 2014
Marc Rubin
Independent Director · since 2018
Elissa Schwartz
Independent Director · since 2020
Harold Shlevin
Independent Director · since 2022
Richard Uihlein
Independent Chairman of the Board · since 2018
Richard Zordani
Independent Director · since 2020
URL
https://galectintherapeutics.com/
IPO date
Sep 04, 2002
Employees
12
Domiciled in
US
Incorporated in
US
Legal address
701 S CARSON ST STE 200
CARSON CITY, NV 89701
US
Headquarters
4960 Peachtree Industrial Boulevard, Suite 240
Norcross, GA 30071
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT